Scopus BioPharma Inc.
SCPSDelisted Mar 3, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001772028
Scopus BioPharma Inc. was delisted on Mar 3, 2023; its insiders filed their last Form 4 on Nov 26, 2021; 15 institutions reported holding it in 13F filings for Q3 2022, worth $110.6K in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in Scopus BioPharma Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −2 vs. Q2 2022
- Shares held
- 465.9K
- −220.8K (−32.2%) vs. Q2 2022
- Total value
- $110.6K
- −$182.4K (−62.2%) vs. Q2 2022
- New holders
- 2
- 1 more added
- Sold out
- 4
- 5 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SCPS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 1 | $0 |
| Q4 2023 | 1 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 1 | $7.49K |
| Q3 2022 | 15 | $110.6K |
| Q2 2022 | 17 | $293.0K |
| Q1 2022 | 19 | $693.0K |
| Q4 2021 | 21 | $4.71M |
| Q3 2021 | 14 | $1.14M |
| Q2 2021 | 15 | $1.07M |
| Q1 2021 | 28 | $4.89M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Scopus BioPharma Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 217,078 | $52.0K | 0.00% | 00.0% | Unchanged |
| M&R Capital Management Inc | 76,819 | $18.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 61,104 | $15.0K | 0.00% | −69,748−53.3% | Reduced |
| Tower Research Capital LLC (TRC) | 26,533 | $6.00K | 0.00% | −1,625−5.8% | Reduced |
| State Street Corp | 20,729 | $5.00K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 14,353 | $3.00K | 0.00% | −43,809−75.3% | Reduced |
| First Manhattan Co | 13,100 | $3.00K | 0.00% | −12,700−49.2% | Reduced |
| Northern Trust Corp | 12,516 | $3.00K | 0.00% | 00.0% | Unchanged |
| Y-Intercept (Hong Kong) Ltd | 10,940 | $2.65K | 0.00% | +10,940 | New |
| JPMorgan Chase & Co | 5,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Compagnie Lombard Odier SCmA | 4,360 | $1.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,254 | $1.00K | 0.00% | +2,154+2,154.0% | Added |
| Wells Fargo & Company | 69 | $0 | 0.00% | −20−22.5% | Reduced |
| Harbour Investments, Inc. | 1,000 | $0 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 2 | $0 | 0.00% | +2 | New |
| Vanguard Group Inc | 0 | $0 | 0.00% | −54,649−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −32,966−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −17,405−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |